Benicar

Benicar

More risks than benefits

Manufactured by Daiichi Sankyo, Benicar is currently prescribed to 64 million patients. Approved in 2002, the drug is used to treat high blood pressure in patients with hypertension.

Benicar is an angiotensin II receptor blocker (ARB) used for the treatment of high blood pressure by relaxing the blood vessels. Currently it is one of eight ARB drugs on the pharmaceutical market.

A federal judicial panel has approved consolidation of the lawsuits claiming that blood-pressure medication Benicar could cause severe gastrointestinal injuries including sprue-like enteropathy. Symptoms can include severe, chronic diarrhea with substantial weight loss.

Patients treated with the blood pressure drug Benicar may be entitled to a settlement as a result of the manufacturer’s failure to warn of the drug’s dangers.

Williams Cuker Berezofsky urges individuals who are taking or who have taken Benicar (even years ago) and experienced severe stomach issues including chronic diarrhea, dehydration, weight loss and pain to call us immediately as lawsuits are currently being filed.

Call for a no cost, no obligation consultation to learn your legal options, 215-557-0099 or fill out this inquiry form to learn more.

The manufacturer of Benicar’s failure to fully research the  side effects and complications, and its failure to warn about these potential risks, have resulted in many Benicar patients being  wrongfully diagnosed with Celiac Disease, or unclassified sprue-like enteropathy.

According to the 2013 FDA warning, sprue-like enteropathy can develop months to years after starting on the drug and sometimes requires hospitalization.

Symptoms and Side Effects

  • Sprue-like enteropathy (chronic diarrhea and dehydration)
  • Villous atrophy which lead to dehydration, malnourishment, and electrolyte problems
  • Contact your health care professional immediately if you take Benicar and experience severe diarrhea, or significant weight loss.

FDA warnings

In 2013, the U.S. Food and Drug Administration (FDA) required the revision of the Benicar drug label to reflect the adverse effects of sprue-like enteropathy. Sprue-like enteropathy is a serious combination of chronic diarrhea and dehydration. If untreated, patients suffering from sprue-like enteropathy can suffer from dire consequences.

Earlier, in 2012, a Mayo Clinic report found that Olmesartan may be associated with a severe form of sprue-like enteropathy. From 2008 to 2011, doctors observed 22 patients who seemingly suffered from Celiac Disease symptoms. Discontinuation of Olmesartan resulted in clinical improvement of sprue-like enteropathy symptoms in all 22 patients.

 

Links

 

Olmesartan Medoxomil: Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy), FDA Drug Safety Communication  2013

Severe Spruelike Enteropathy Associated With Olmesartan, The Mayo Clinic, August 2012